Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We design, develop, manufacture and commercialize a broad suite of precision guided therapy tools including intravascular ultrasound, or IVUS, and fractional flow reserve, or FFR, products. We believe that these products enhance the diagnosis and treatment of vascular heart disease by improving the efficiency and efficacy of existing diagnostic angiograms, percutaneous interventional, or PCI, therapy procedures in the coronary arteries or peripheral arteries and veins. We are facilitating the adoption of functional PCI, in which our FFR technology is used to determine whether or not a stent is necessary, and IVUS is used to guide stent placement and optimization. We market our products to physicians, nurses and technicians who perform a variety of endovascular based coronary and peripheral interventional procedures in hospitals and to other personnel who make purchasing decisions on behalf of hospitals. ... More ...
Analyst Info |
|
| Annual EPS Est: | $0.15 |
| Quarterly EPS Est: | 0 |
| PEG Ratio: | 21.53 |
|
Mean Recommendation: View Summary / View All |
1.93 |
Data is provided by Zacks Investment Research
